Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E34.42 EPS (ttm)1.83 Insider Own0.04% Shs Outstand2.78B Perf Week-0.80%
Market Cap174.53B Forward P/E16.37 EPS next Y3.84 Insider Trans-39.32% Shs Float2.76B Perf Month7.56%
Income5.13B PEG5.48 EPS next Q0.99 Inst Own75.00% Short Float1.03% Perf Quarter12.19%
Sales39.44B P/S4.42 EPS this Y-61.60% Inst Trans0.06% Short Ratio2.87 Perf Half Y27.30%
Book/sh15.66 P/B4.01 EPS next Y2.54% ROA5.20% Target Price65.47 Perf Year18.33%
Cash/sh4.26 P/C14.75 EPS next 5Y6.29% ROE11.60% 52W Range46.88 - 64.00 Perf YTD21.01%
Dividend1.84 P/FCF36.76 EPS past 5Y41.50% ROI6.40% 52W High-1.80% Beta0.65
Dividend %2.93% Quick Ratio1.50 Sales past 5Y-3.00% Gross Margin63.20% 52W Low34.06% ATR0.90
Employees68000 Current Ratio1.90 Sales Q/Q0.60% Oper. Margin18.10% RSI (14)60.59 Volatility1.27% 1.68%
OptionableYes Debt/Eq0.56 EPS Q/Q79.20% Profit Margin13.00% Rel Volume0.79 Prev Close62.32
ShortableYes LT Debt/Eq0.55 EarningsJul 29 BMO Payout99.50% Avg Volume9.88M Price62.85
Recom2.50 SMA201.47% SMA505.46% SMA20015.68% Volume7,793,780 Change0.85%
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Aug-27-16 09:44AM  Saturday links: bad intentions
Aug-25-16 11:04AM  AstraZenecas Recent Product Developments
Aug-24-16 04:53PM  Merck Offers Value and Steady Dividend Growth
03:42PM  Health-care sector trails broader market as pricing issues reinflamed at MarketWatch
11:04AM  Performance of AstraZenecas RI&A Segment in 2Q16
11:04AM  How Did Bristol-Myers Squibb Fare in 2Q16?
10:00AM  Write A Prescription For More Pharma M&A With This ETF
Aug-23-16 11:04AM  Whats Challenging Novos Leadership in the US Diabetes Space?
09:50AM  Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors
12:09AM  [$$] Pfizers Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
Aug-22-16 01:14PM  Why Did Novos Valuation Multiple Fall Recently?
12:36PM  Monday links: work and drudgery
12:22PM  [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
09:53AM  Pfizer Will Buy Cancer Drugmaker Medivation For $14 Billion
09:06AM  How Did Bristol-Myers Squibbs Oncology Segment Perform in 2Q16?
Aug-21-16 12:33PM  Curbing Excessive Exuberance May be Premature
Aug-18-16 12:50PM  How Much Medivation Can Really Fetch in a Buyout at 24/7 Wall St.
11:38AM  2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now at Motley Fool
Aug-17-16 04:32PM  Merck Among Drug Giants Looking To Buy Medivation, Says Report
03:24PM  Gilead Sciences: Still Dominating Hepatitis C But at Barrons.com
01:51PM  How Will Merck (MRK) Stock React to Potential Medivation Bid?
01:03PM  [$$] Gilead: breaking the fever at Financial Times
11:04AM  What Do Analysts Estimate for Merck?
09:04AM  Is Valeants Xifaxan Resuming Growth?
09:04AM  How Did Mercks Animal Health Segment Perform?
07:30AM  Lux Research Names Mike Coyne as New CEO Marketwired
Aug-16-16 04:26PM  Pfizer's Bold Bid to Conquer Cancer at Motley Fool
11:04AM  Remicade Is Driving Down Mercks Immunology Franchise
10:11AM  Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
09:05AM  Why Gardasil Is So Important to Mercks Vaccines Business
Aug-15-16 07:50PM  Merck cutting 148 Montco jobs at bizjournals.com
01:05PM  Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis at 24/7 Wall St.
11:05AM  Keytruda: Mercks Immuno-oncology Blockbuster
10:38AM  Inovio Expands Enrollment in Ebola Vaccine Phase I Study
09:30AM  Jobs at these 10 companies will literally pay you for life
09:06AM  What Are Mercks Key Diabetes Products?
09:04AM  Recent Corporate and Pipeline Developments for Pfizer
Aug-14-16 03:02PM  Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow at Motley Fool
Aug-13-16 01:04PM  MERCK & CO., INC. Financials
Aug-12-16 05:17PM  Whats Contributing to Mercks Growth?
05:17PM  Is Mercks Valuation Improving?
03:39PM  Merck: Biotech and Pharmaceuticals Giant
01:17PM  Top 3 Research Reports for August 12, 2016
Aug-11-16 08:38PM  Gilead to get attorney fees in hepatitis C patent fight with Merck Reuters
Aug-10-16 06:40PM  After Opdivo's Failure, Is Merck a Better Buy Than Bristol-Myers? at Motley Fool
03:45PM  Immune Design (IMDZ) Posts Wider-than-Expected Q2 Loss
12:09PM  Solar Stocks Weigh On Nasdaq; Disney Leads Dow; Alibaba On The Move
12:04PM  Pfizers Business Segments and Their Performance
11:42AM  Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target
09:07AM  An Update on Analyst Recommendations for Novo
09:05AM  Major Pharma Short Interest Slides at 24/7 Wall St.
08:05AM  Short Sellers Look Worried About High-Yield Defensive Dividend Stocks at 24/7 Wall St.
Aug-09-16 10:28PM  Why Is Pfizers Valuation Low Compared to Its Peers?
04:01PM  Amex, DuPont Drag on DJIA Tuesday at 24/7 Wall St.
01:11PM  Stocks pare gains as oil reverses at MarketWatch
11:49AM  Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
10:10AM  Stock Market News for August 09, 2016
10:00AM  Don't Write Off Bristol-Myers After Opdivo Setback
06:15AM  In change of tack, UK agency backs Amgen virus-based cancer drug
12:08AM  [$$] Allergan Revenue Increases, Though Loss Widens at The Wall Street Journal
Aug-08-16 06:33PM  US Market Indexes Close Lower on Monday
05:05PM  Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine Business Wire
04:41PM  MERCK & CO., INC. Files SEC form 10-Q, Quarterly Report
04:25PM  US STOCKS-Wall Street takes tiny step back from record highs
04:24PM  Stocks retreat from all-time high to end slightly lower at MarketWatch
04:03PM  Stocks Retreat From Records as Health Care Slumps
04:01PM  Healthcare Stocks Sink DJIA on Monday at 24/7 Wall St.
03:22PM  The Ironic Chess Game of Bristol-Myers
02:50PM  Stocks Fall as Health Care Selloff Counters Energy Rally
02:26PM  [$$] Allergan Revenue Increases, Though Loss Widens at The Wall Street Journal
02:25PM  ETFs with exposure to Merck & Co., Inc. : August 8, 2016
01:05PM  Bristol-Myers: Lung Cancer Failure 'Too Significant' To Stay Bullish at Barrons.com
12:45PM  Why Credit Suisse Sees Merck and Bristol-Myers Gap Widening Further at 24/7 Wall St.
10:32AM  Why Merck's Lung Cancer Success Won't Last at Barrons.com
10:10AM  Stock Market News for August 08, 2016
10:03AM  Merck Gets a Big Shot in the Arm
10:00AM  Bristol-Myers' stock extends slide after downgrade, Merck upgraded at MarketWatch
09:55AM  Merck (MRK) Stock Upgraded at Credit Suisse
09:31AM  Priceline trade offers a 4% return in 74 days, or find similar option trades on Marathon Oil Corporation, Sears Holdings, Merck & Company Incorporated, and TASER International PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: ExxonMobil, Chevron, Merck, Pfizer and Procter & Gamble
09:24AM  Blog Coverage Announced for Bristol Myers
08:46AM  4 Big-Volume Stocks to Add to Your Buy List -- Plus 3 to Avoid
08:16AM  Morning Movers: MFRM, DAL, AMZN, BMY
06:45AM  REPEAT/FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy Business Wire
Aug-07-16 08:30PM  What Next for Bristol-Myers and Merck?
07:48PM  Top Stock Holdings Of Hottest Growth Mutual Funds Since Brexit
09:15AM  Lets Get Real!
Aug-06-16 12:07PM  Why Bristol-Myers lung-cancer drug could still succeed despite stunning trial failure at MarketWatch
12:25AM  Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study at The Wall Street Journal
12:01AM  [$$] Bristol-Myers Squibb's Bad News Buoys Merck at Barrons.com
Aug-05-16 08:59PM  Takeaways, Observations and Tesla: Best of Kass +10.41%
07:30PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy Business Wire
07:16PM  U.S. Market Indexes Higher After Positive Jobs Report
04:59PM  Bristol-Myers Investors Feel the Harsh Downside of Cancer Bet at Bloomberg
04:49PM  Bristol-Myers Plunges On Surprise Opdivo Failure In Lung Cancer
04:43PM  S&P 500, Nasdaq ring up records after stellar jobs report at MarketWatch
04:37PM  Bristol-Myers drug fails lung cancer study, shares plunge
04:24PM  Bristol-Myers Squibb (BMY) Stock Downgraded at Morgan Stanley
04:18PM  Jobs Data Spur Big Gains For Stocks; Financials Lead, Utilities Lag
04:01PM  Merck Dominates DJIA Boost Friday at 24/7 Wall St.
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM